Evidence map›Paper›PMID 36759006›Full record

ArticleRMD open2023

Patients with osteoporosis: children of a lesser god.

Giovanni Adami, Elena Tsourdi, Maurizio Rossini, Thomas Funck-Brentano, Roland Chapurlat

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Giovanni AdamiRheumatology Unit, Department of Medicine, University of Verona, Verona, Italy adami.g@yahoo.com.ORCID 0000-0002-8915-0755
Elena TsourdiDivision of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III & Center for Healthy Aging, Technical University Medical Center, Dresden, Germany.
Maurizio RossiniRheumatology Unit, Department of Medicine, University of Verona, Verona, Italy.
Thomas Funck-BrentanoBIOSCAR UMR 1132, INSERM, Université Paris Cité, Paris, France.
Roland ChapurlatINSERM, UMR 1033, Université Claude Bernard Lyon1, Lyon, France.
University of Verona · ITInserm · FRTechnische Universität Dresden · DEUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis is a common non-communicable disease with enormous societal costs. Antiosteoporosis medications have been proven efficacious in reducing the refracture rate and mortality; moreover, we have now convincing evidence about the cost-effectiveness of antiosteoporotic medications. However, albeit preventable and treatable, osteoporosis has been somehow neglected by health authorities. Drugs approval has been unnecessarily lengthy, especially when compared with other non-communicable diseases. Herein, we discuss the issue of procrastinating drug approval in osteoporosis and future implications.

Indexed as

Drug ApprovalOsteoporosisHumansOsteoporosisOutcome and Process Assessment, Health CareOutcome Assessment, Health Care

Identifiers

PMID36759006
PMCPMC9923352
OpenAlexW4319730822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.